107 Blood biomarkers during and after treatment The course of both HS-TNT (p<0.01) and NT-ProBNP (p<0.01) levels were significantly different for patients with new cardiac events versus for those without (Figures 2B and D). The difference in the course of HS-TNT levels was most pronounced in time frame 3 (between 4 weeks and 6 months after treatment) while a trend was seen in time frame 2 (between end of treatment and 4 weeks). Regarding NTProBNP, a significant difference was only found in time frame 3 (p<0.01). Patients with a history of cardiac events prior to treatment had significantly higher levels of HS-TNT (p<0.01) and NT-ProBNP (p<0.01) at baseline, but the overall course of these biomarkers was similar to those observed among patients without a history of cardiac events. Interestingly, patients without a cardiac history showed significantly better recovery of HS-TNT-levels after treatment compared to those with a cardiac event history (p=0.03) (Figures 2A and C). For patients with, or without new pulmonary events, no significant differences in the course of HS-TNT or NT-ProBNP levels were observed. However, there was a trend towards a stronger rise in HS-TNT (p=0.07) for patients with new pulmonary events, as compared to those without (Figure 2E and F) . 7
RkJQdWJsaXNoZXIy MTk4NDMw